ANIP - ANI Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

ANI Pharmaceuticals, Inc.

210 Main Street West
Baudette, MN 56623
United States
218-634-3500
http://www.anipharmaceuticals.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees299

Key Executives

NameTitlePayExercisedYear Born
Mr. Arthur S. PrzybylPres, CEO & Director1.18MN/A1957
Mr. Stephen P. CareyCFO & VP of Fin.577.23kN/A1971
Mr. James G. MarkenSr. VP of Operations & Product Devel.509.26kN/A1963
Mr. Robert W. SchrepferSr. VP of Bus. Devel. & Specialty Sales576kN/A1972
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.

Corporate Governance

ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.